<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report the case of a 59-year-old woman treated for a <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) who developed cytomegalovirus (CMV) <z:hpo ids='HP_0002583'>colitis</z:hpo> during induction therapy combining fludarabine, <z:chebi fb="0" ids="28680">cytarabine</z:chebi> and <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> occurred rarely during <z:chebi fb="0" ids="28680">cytarabine</z:chebi> and anthracyclin based induction therapy for <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> is usually observed in immunocompromised patients but some cases have been recently observed in patients after autologous stem-cell transplantation with or without CD34 + stem-cell selection </plain></SENT>
<SENT sid="3" pm="."><plain>We discuss this case and issues arising from it in relation to the use of combination of high-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> and fludarabine </plain></SENT>
</text></document>